Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cetuximab- or bevacizumab-based chemotherapy for unresectable colorectal liver metastases
2011-003288-31Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Oct 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, bevacizumab, irinotecan, oxaliplatin, fluorouracil in metastatic colorectal adenocarcinoma (mCRC), colorectal cancer liver metastasis (CRLM), sponsored by Technische Universität Dresden. Started Oct 2011; status: terminated.
02
Drugs
cetuximabbevacizumabirinotecanoxaliplatinfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2011-003288-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003288-31.